News | PET Imaging | August 24, 2018

Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Military personnel show brain changes similar to those seen in retired football players with suspected CTE on PET scans

Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

August 24, 2018 — In a small study of military personnel who had suffered head trauma and had reported memory and mood problems, researchers found brain changes similar to those seen in retired football players with suspected chronic traumatic encephalopathy (CTE).

CTE occurs in people who have had multiple head injuries. Recent studies and headlines have focused on former football players who exhibited symptoms such as depression, confusion and mood swings. In later stages, CTE can lead to symptoms of Alzheimer's disease and other forms of dementia. Currently, CTE can only be diagnosed after death, when examination of brain tissue reveals clumps of a protein called tau, which kills brain cells.

To aid in diagnosing CTE in living individuals, researchers at the University of California Los Angeles (UCLA) are studying a molecular tracer, called FDDNP, which binds with tau as well as another abnormal protein called amyloid. The tracer, given intravenously, shows up in positron emission tomography (PET) brain scans, pointing to the location and extent of abnormal proteins in the brain.

Previously, UCLA researchers used the tracer to study the brains of 15 former National Football League (NFL) players with memory and mood problems. In that study, the pattern of abnormal protein distribution in living patients was consistent with the tau distribution seen in autopsy-confirmed CTE cases.

For the current study, which builds upon the earlier research, seven military personnel (five veterans and two in active duty) who had suffered mild traumatic brain injuries and had memory or mood complaints underwent neuropsychiatric evaluations. They had brain scans after being injected with FDDNP, the molecular tracer. The results were compared to those of the 15 previously studied football players, as well as 24 people with Alzheimer's dementia and 28 people without cognitive problems, for comparison.

The location and quantity of the tracer in the brains of the military personnel were similar to that seen in retired football players and distinct from the distribution patterns seen in people with Alzheimer's disease or in healthy individuals.

Larger studies using FDDNP and brain scans in people at risk for chronic traumatic encephalopathy are needed to confirm the usefulness of FDDNP as a diagnostic tool. The ability to diagnose CTE in living individuals would help scientists observe the progression of the disease, develop treatments and quantify the scope of CTE among different populations, such as military veterans.

Gary Small, M.D., a professor of psychiatry and biobehavioral sciences at UCLA and director of the Longevity Center at UCLA's Semel Institute for Neuroscience and Human Behavior, is the study's senior author. The study appears in the July 17 Journal of Alzheimer's Disease.

For more information: www.j-alz.com

Reference

Small G.W., Chen S., Siddarth P., et al. FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy. Journal of Alzheimer’s Disease, Aug. 7, 2018. DOI: 10.3233/JAD-171152

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Computer-Aided Detection Software | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Feature | Artificial Intelligence | May 17, 2019 | Inga Shugalo
With its increasing role in medical imaging,...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Videos | Advanced Visualization | May 16, 2019
This is an example of how virtual reality is being used in neuro-radiology to better evaluate patients using advanced